Megan E. Sullivan

Megan E. Sullivan

Auto-generated profile, based on publicly available information

Megan E. Sullivan

Brigham and Women’s Hospital 1 Division of Hematology, Department of Medicine Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Cancer Research Communications
Verified
Journal Article
Open access
MSMargaret R. Smith-Oliver
Margaret R. Smith-Oliver
DGDeepa Gautam
Deepa Gautam
GPGrace C. Petrarca
Grace C. Petrarca
MSMegan E. Sullivan
Megan E. Sullivan
ECEmily M. Clarke
Emily M. Clarke
EBElisabeth M. Battinelli
Elisabeth M. Battinelli
Tumor-associated platelets (TAP), which are reprogrammed by tumor-derived signals to acquire immunosuppressive properties, represent an emerging mechanism of immune evasion in triple-negative breast cancer (TNBC). Although immune checkpoint inhibitors have shown promise, their efficacy is frequently limited by T-cell exhaustion and therapeutic resistance. In this study, we demonstrate that TAPs, unlike healthy circulating platelets, induce T-cell dysfunction through platelet-derived P-selectin, which engages P-selectin glycoprotein ligand 1 (PSGL-1) on T cells. This interaction promotes immunosuppressive signaling, driving T-cell exhaustion and impairing antitumor cytotoxicity. Using in vitro coculture systems and in vivo TNBC models, we show that disruption of the P-selectin–PSGL-1 axis, including pharmacologic blockade with the FDA-approved anti–P-selectin antibody crizanlizumab, restores T-cell function and enhances responsiveness to immune checkpoint blockade. Notably, PSGL-1, traditionally recognized for its role in leukocyte trafficking and immune regulation, is co-opted by TAPs to suppress T-cell activity, revealing a mechanism of platelet-mediated immune modulation. These findings establish TAPs as active regulators of antitumor immunity and identify the P-selectin–PSGL-1 axis as a therapeutically actionable target to overcome resistance to immunotherapy in TNBC. Significance: Tumor-associated platelets help TNBCs evade immune attack by suppressing T-cell function through P-selectin signaling. Blocking this pathway with crizanlizumab restores antitumor immunity and enhances response to immunotherapy, identifying a promising new combination treatment strategy for patients with this aggressive form of breast cancer.


10 July 2026
Verified
Other
Open access
MSMargaret R. Smith-Oliver
Margaret R. Smith-Oliver
DGDeepa Gautam
Deepa Gautam
GPGrace C. Petrarca
Grace C. Petrarca
MSMegan E. Sullivan
Megan E. Sullivan
ECEmily M. Clarke
Emily M. Clarke
EBElisabeth M. Battinelli
Elisabeth M. Battinelli
Gating strategies used to identify different T cell types in mouse

10 July 2026
Verified
Other
Open access
MSMargaret R. Smith-Oliver
Margaret R. Smith-Oliver
DGDeepa Gautam
Deepa Gautam
GPGrace C. Petrarca
Grace C. Petrarca
MSMegan E. Sullivan
Megan E. Sullivan
ECEmily M. Clarke
Emily M. Clarke
EBElisabeth M. Battinelli
Elisabeth M. Battinelli
Platelet expression of immune regulatory molecules